Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impaired Spindle Assembly Checkpoint In Vivo Promotes MDS/AML in a Novel Mouse Model of Fanconi Anemia

Donna Cerabona, Zahi Abdul Sater, Elizabeth Sierra Potchanant, PhD, Ying He, Zejin Sun, MD PhD, Grzegorz Nalepa, MDPhD

Blood (2015) 126 (23): 1211.

https://doi.org/10.1182/blood.V126.23.1211.1211

Published: 2015

Journal Articles

Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML.

Moshe Ornstein, MD, MA, Sudipto Mukherjee, MD PhD, Sanjay R. Mohan, MD, Paul Elson, ScD, Ramon V. Tiu, MD, Yogenthiran Saunthararajah, M.D., Leslie Farhat, Cassandra Kendeigh, Anjali Advani, MD, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD, PhD, Mikkael A. Sekeres, MD, MS

Blood (2012) 120 (21): 2589.

https://doi.org/10.1182/blood.V120.21.2589.2589

Published: 2012

Journal Articles

Anti CD-30 Antibody-Drug Conjugate Brentuximab Vedotin (ADCETRIS ® ) May Be a Promising Treatment Option for Systemic Mastocytosis (SM).

Amitkumar Mehta, Vishnu V B Reddy, MD, Uma Borate, MD, MS

Blood (2012) 120 (21): 2857.

https://doi.org/10.1182/blood.V120.21.2857.2857

Published: 2012

Journal Articles

A Rationale to Enhance the Response to Antimitotic Therapy in Acute Myeloid Leukemia

Dominik Schnerch, MD, Julia Felthaus, Monika Engelhardt, Ralph Wäsch, MD

Blood (2012) 120 (21): 1332.

https://doi.org/10.1182/blood.V120.21.1332.1332

Published: 2012

Journal Articles

A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),

Alice C Fan, MD, Liwen Xu, PhD, Kunju J Sridhar, PhD, Mai Tran, Prajna Banerjee, PhD, John P. Renschler, Radha Tripuraneni, MD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD, Dean W. Felsher, MD, PhD

Blood (2011) 118 (21): 3808.

https://doi.org/10.1182/blood.V118.21.3808.3808

Published: 2011

Journal Articles

Two New Classes of Drugs to Target Chemotherapy Resistant and High Risk B-ALL

Cathy A. Swindlehurst, PhD, Leah Fung, PhD, Kyle W.H. Chan, PhD, Sabine Ottilie, PhD, Ashkan Shahbandi, Christopher L. Morris, MD, PhD, Oliva L Francis, Terrence Bennet, Shannalee R Martinez, Kimberly J Payne, PhD

Blood (2011) 118 (21): 2590.

https://doi.org/10.1182/blood.V118.21.2590.2590

Published: 2011

Journal Articles

The Spindle Checkpoint Protein BubR1 Is Differentially Expressed in the Lymphatic and Myeloid Lineage and Is a Determinator of Response to Spindle Poisons

Dominik Schnerch, MD, Marie Follo, PhD, Andrea Schmidts, Julika Krohs, Julia Felthaus, Monika Engelhardt, MD, Ralph Wäsch

Blood (2011) 118 (21): 1407.

https://doi.org/10.1182/blood.V118.21.1407.1407

Published: 2011

Journal Articles

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Mahesh Seetharam, MD, Mai Tran, Alice C. Fan, MD, Liwen Xu, PhD, John P. Renschler, Dean W. Felsher, MD, PhD, Kunju Sridhar, PhD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD

Blood (2010) 116 (21): 4010.

https://doi.org/10.1182/blood.V116.21.4010.4010

Published: 2010

Journal Articles

Malignancies and Outcome in Patients with Ataxia-Telangiectasia: Results From the French National Registry for Primary Immune Deficiencies.

Felipe Suarez, MD, PhD, Julien Beauté, MD, MPH, NIzar Mahlaoui, MD, MSc, Romain Micol, MD, MPH, Olivier Hermine, MD, PhD, Dominique stoppa-Lyonnet, MD, PhD, Alain Fischer, MD, PhD

Blood (2009) 114 (22): 1101.

https://doi.org/10.1182/blood.V114.22.1101.1101

Published: 2009

Journal Articles

A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.

Guillermo Garcia-Manero, MD, H. Jean Khoury, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Tapan Kadia, MD, Zeev Estrov, MD, Elias Jabbour, MD, Maria Cielo Foudray, RN, Martha Arellano, Amelia Langston, MD, Beverly Bethelmie-Bryan, Selena Rush, Burgess Freeman, Heidi Simmons, PhD, Mieke Ptaszynski, Hagop Kantarjian, MD

Blood (2009) 114 (22): 2047.

https://doi.org/10.1182/blood.V114.22.2047.2047

Published: 2009

Journal Articles

NK-Cell Lymphoma Shares Strikingly Similar Molecular Features with a Distinct Set of γδ T-Cell Lymphoma and Identification of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent.

Blood (2009) 114 (22): 313.

https://doi.org/10.1182/blood.V114.22.313.313

Published: 2009

Journal Articles

Pharmacokinetics of Anti-CD22 Antibody Conjugates with Uncleavable and Cleavable Linkers in Rats.

Blood (2007) 110 (11): 2361.

https://doi.org/10.1182/blood.V110.11.2361.2361

Published: 2007

Journal Articles

Non-Clinical Pharmacology of Anti-CD22 Antibody Drug Conjugates.

Dong Xie, Jakub Baudys, Pam Chan, Rong Deng, Randy Dere, Allen Ebens, Paul Fielder, Franklin Fuh, Reina Fuji, Alane Gray, Catherine Huang, Shasha Jumbe, Kathleen Makeever, Ola Saad, Jean-Philippe Stephan, Jay Tibbitts, Marna Williams, Shang-Fan Yu, Saileta Prabhu

Blood (2007) 110 (11): 2363.

https://doi.org/10.1182/blood.V110.11.2363.2363

Published: 2007

Journal Articles

The Impact of Telomere Shortening in Dyskeratosis Congenita Cells on DNA Damage Response Pathways.

Travis Witt, BS, Aloysius Klingelhutz, PhD, Erik Westin, BS, Preeti Satyanarayana, MD, Peter M. Lansdorp, MD, PhD, Frederick D. Goldman, MD

Blood (2007) 110 (11): 4052.

https://doi.org/10.1182/blood.V110.11.4052.4052

Published: 2007

Journal Articles

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

Todd A. Hembrough, Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, Mark R. Bray

Blood (2007) 110 (11): 1209.

https://doi.org/10.1182/blood.V110.11.1209.1209

Published: 2007

Journal Articles

ARRY-429520, a KSP Inhibitor with Efficacy in Animal Models of Solid and Liquid Tumors.

Rich Woessner, PhD, Chris Corrette, Ph.D., Shelley Allen, Ph.D., Jeremy Hans, Ph.D., Qian Zhao, Ph.D., Tom Aicher, Ph.D., Joe Lyssikatos, Ph.D., John Robinson, Ph.D., Greg Poch, Ph.D., Laura Hayter, A.S., April Cox, M.S., Patrice Lee, Ph.D., James Winkler, Ph.D., Kevin Koch, Ph.D., Eli Wallace, Ph.D.

Blood (2006) 108 (11): 4388.

https://doi.org/10.1182/blood.V108.11.4388.4388

Published: 2006

Journal Articles

Oral Administration of the Opium Alkaloid Noscapine (NOS) Exhibits Potent Anti-Tumor Activity Against Non-Hodgkin’s Lymphomas and Myeloma Cell Lines In Vitro and In Vivo in SCID-beige Murine Xenograft Models.

Owen O’Connor, MD, PhD, J. Mastrella, E. Smith, L. Toner, A. Auerbach, J. P. Leonard, MD

Blood (2005) 106 (11): 2427.

https://doi.org/10.1182/blood.V106.11.2427.2427

Published: 2005

NARROW

Impaired Spindle Assembly Checkpoint In Vivo Promotes MDS/AML in a Novel Mouse Model of Fanconi Anemia

Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML.

Anti CD-30 Antibody-Drug Conjugate Brentuximab Vedotin (ADCETRIS ® ) May Be a Promising Treatment Option for Systemic Mastocytosis (SM).

A Rationale to Enhance the Response to Antimitotic Therapy in Acute Myeloid Leukemia

A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),

Two New Classes of Drugs to Target Chemotherapy Resistant and High Risk B-ALL

The Spindle Checkpoint Protein BubR1 Is Differentially Expressed in the Lymphatic and Myeloid Lineage and Is a Determinator of Response to Spindle Poisons

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Malignancies and Outcome in Patients with Ataxia-Telangiectasia: Results From the French National Registry for Primary Immune Deficiencies.

A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.

NK-Cell Lymphoma Shares Strikingly Similar Molecular Features with a Distinct Set of γδ T-Cell Lymphoma and Identification of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent.

Pharmacokinetics of Anti-CD22 Antibody Conjugates with Uncleavable and Cleavable Linkers in Rats.

Non-Clinical Pharmacology of Anti-CD22 Antibody Drug Conjugates.

The Impact of Telomere Shortening in Dyskeratosis Congenita Cells on DNA Damage Response Pathways.

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

ARRY-429520, a KSP Inhibitor with Efficacy in Animal Models of Solid and Liquid Tumors.

Oral Administration of the Opium Alkaloid Noscapine (NOS) Exhibits Potent Anti-Tumor Activity Against Non-Hodgkin’s Lymphomas and Myeloma Cell Lines In Vitro and In Vivo in SCID-beige Murine Xenograft Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only